4 recruiting. 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 4 |
| Phase 2 | 4 | Recruiting 4 |
Follow Avenzo Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) AVZO-103, Combination Agent - Solid Tumor Cancer, Locally Advanced | Phase 1 / Phase 2 | Recruiting | Avenzo Therapeutics, Inc. | 355 | 2025-10-02 | 2026-10-05 |
| ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors AVZO-021, Fulvestrant, Letrozole - HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer | Phase 1 / Phase 2 | Recruiting | Avenzo Therapeutics, Inc. | 380 | 2025-08-20 | 2026-08-10 |
| AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) AVZO-1418, Combination Agent 1, Combination Agent 2 - Solid Tumor Cancer, Locally Advanced | Phase 1 / Phase 2 | Recruiting | Avenzo Therapeutics, Inc. | 480 | 2025-06-04 | 2026-10-16 |
| Study of AVZO-021 in Patients With Advanced Solid Tumors AVZO-021, Palbociclib, Fulvestrant - Advanced Solid Tumor, HR+/HER2- Breast Cancer | Phase 1 / Phase 2 | Recruiting | Avenzo Therapeutics, Inc. | 430 | 2023-08-30 | 2026-09-28 |
Neoplasm Metastasis (2) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Ovarian Epithelial (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Lung Neoplasms (1) · Nasopharyngeal Neoplasms (1) · Small Cell Lung Carcinoma (1) · Triple Negative Breast Neoplasms (1)
Fulvestrant (2) · Letrozole (2) · Carboplatin (1) · abemaciclib (1) · palbociclib (1) · ribociclib (1) · sacituzumab govitecan (1)
United States (4) · Australia (1) · China (1)